U.S. markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.51-0.11 (-1.44%)
At close: 04:00PM EST
7.62 +0.11 (+1.46%)
After hours: 04:49PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close7.62
Bid7.35 x 1100
Ask8.00 x 4000
Day's Range7.51 - 7.99
52 Week Range5.41 - 29.90
Avg. Volume1,901,148
Market Cap689.772M
Beta (5Y Monthly)3.41
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MCRB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Seres Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 01/20/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Benzinga

    Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection

    Seres Therapeutics Inc (NASDAQ: MCRB) has announced the publication of data from Phase 3 ECOSPOR III study SER-109 for recurrent C. difficile infection (rCDI). The New England Journal of Medicine (NEJM) publication highlights that SER-109 was superior to placebo in reducing CDI recurrence, with 88% of SER-109 patients achieving a sustained clinical response compared to 60% on placebo. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spo

  • Business Wire

    New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection

    CAMBRIDGE, Mass., January 19, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI). The publication highlights data that found SER-109 to be superior to placebo in reducing CDI recurrence, with 88% of SER-109 patie

  • Investopedia

    Top Biotech Stocks for Q1 2022

    The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.